VERAXA Appoints Willener CFO As Pipeline Advances; Stock Up
(RTTNews) - VERAXA Biotech AG (VRXA), a cancer therapeutics company, on Friday announced the appointment of Raju Willener as Chief Financial Officer (CFO).
He succeeds Carl von Halem, who was appointed interim CFO following the departure of Torsten Burgermeister from the role in July 2026. Burgermeister oversaw VERAXA's transition to a publicly trading company in June 2026.
The company highlighted Willener's three decades of experience as a financial executive, gained in roles such as CFO, Chief Investment Officer, Country Head, and Head of Corporate Finance. He previously served as Director of Corporate Development, and later CFO, at Exentis AG. He has also performed as a senior executive and investment leader in various investment firms and global financial institutions. VERAXA is currently advancing a diversified pipeline of active T cell engagers (BiTAC-TCEs), bispecific antibody-drug conjugates (bsADCs), and proprietary BiTAC formats toward clinical development.
VRXA closed Thursday at $1.53, up 10.87%.
